Gland Pharma Limited
GLAND
Rank in Stocks
#3302
Gland Pharma Limited, established in Hyderabad, India, in 1978, is a... Gland Pharma Limited, established in Hyderabad, India, in 1978, is a pharmaceutical company that specializes in the creation, production, and global distribution of generic injectable medications. Its product line features key active pharmaceutical ingredients such as heparin sodium, enoxaparin sodium, rocuronium bromide, and daptomycin injections, among others. The company's extensive therapeutic portfolio encompasses anti-infectives, anesthetics, anticoagulants, antimalarials, cardiovascular drugs, gastrointestinal treatments, pain management, hormones, fertility aids, anti-cancer agents, gynecological remedies, neurological and central nervous system medications, respiratory treatments, blood-related products, ophthalmological and otological solutions, orthopedics, hematinics, and various vitamins, minerals, and nutrients. Additionally, Gland Pharma provides contract development services. The company primarily operates on a business-to-business (B2B) model, distributing its products across major markets including the United States, Europe, Canada, Australia, India, and other international territories. Gland Pharma Limited functions as a subsidiary of Fosun Pharma Industrial Pte. Ltd.
Share Price
$32.32
Market Cap
$5.33B
Change (1 day)
-3.01%
Change (1 year)
47.99%
Country
IN
Trade Gland Pharma Limited (GLAND)
Category
Healthcare
Revenue for Gland Pharma Limited (GLAND)
Revenue in Jun 2026 TTM: $742.20M
According to Gland Pharma Limited latest financial reports the company's current revenue (TTM) is $742.20M. In 2024 the company made a revenue of $679.36M an increase over the revenue in the year 2023 that was $441.05M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Gland Pharma Limited from 2017 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2026 (TTM) | $742.20M | 13.02% |
| 2025 | $656.70M | -3.34% |
| 2024 | $679.36M | 54.03% |
| 2023 | $441.05M | -23.92% |
| 2022 | $579.73M | 22.55% |
| 2021 | $473.05M | 35.33% |
| 2020 | $349.54M | 18.74% |
| 2019 | $294.38M | 18.32% |
| 2018 | $248.80M | 9.08% |
| 2017 | $228.10M | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | 790.82% |
IN
|
